Doximity (NYSE:DOCS) experienced a dramatic stock surge on Friday, with shares climbing 32.6% to close at $27.40. The rally added approximately $1.2 billion to the company's market capitalization, despite a mixed fiscal first-quarter earnings report and a reduced full-year adjusted EBITDA forecast.
The stock's weekly gain was 31.0%, significantly outperforming the broader market. The Nasdaq Composite rose 1.30% on Friday and 5.19% for the week, while the S&P 500 advanced 0.62% and 3.58%, respectively. The Dow Jones Industrial Average gained 0.28% on the day and 2.96% for the week.
Earnings and Guidance Disconnect
Doximity reported fiscal Q1 2027 revenue of $156.6 million, beating consensus estimates of $151.7 million by 3.2% and representing a 7% year-over-year increase. However, non-GAAP diluted EPS came in at $0.29, one cent below the consensus estimate of $0.30. Adjusted EBITDA fell 6.3% to $74.8 million from $79.8 million a year earlier, while free cash flow dropped 34.1% to $39.6 million.
The company raised its full-year revenue guidance midpoint by $6 million to $676 million, but lowered its adjusted EBITDA guidance midpoint by $10 million to $319 million. The stock's Friday gain was roughly 200 times the incremental revenue guidance, highlighting the market's focus on future AI-driven growth rather than current financials.
AI Engagement Metrics Rise
CEO Jeff Tangney highlighted "another quarter of record engagement." Workflow active prescribers grew over 30% year-over-year, and AI Search queries increased by more than 25% sequentially. These metrics suggest growing adoption of Doximity's AI-powered tools, though the company has yet to translate this into significant revenue.
Investors appear to be pricing in AI revenue beyond the current outlook. However, costs are rising: research and development expenses increased 44% to $38.5 million, stock-based compensation jumped 68% to $36.8 million, and non-GAAP gross margin declined by 3.7 percentage points.
Analyst Reactions and Price Targets
Analyst updates were mixed. Needham's Scott Berg raised his price target from $27 to $41, while Raymond James increased its target from $23 to $38. However, Bank of America maintained a sell rating with a $20 target, implying a 27% downside. The average analyst price target stood at $28.88, a 5.4% premium to Friday's close.
Morgan Stanley's Craig Hettenbach called the quarter "a solid beat" but noted the guidance was "mixed." Canaccord's Richard Close cautioned that AI revenue has "truly yet to hit the P&L." The stock's intraday high of $40, followed by a close 31.5% below that peak, underscores the volatility and uncertainty surrounding the AI narrative.
Market Context and Upcoming Catalysts
The broader market advanced following a disappointing July employment report, with the S&P 500 reaching a new high. Doximity outperformed the Nasdaq by nearly 26 percentage points for the week.
Investors are now looking ahead to July CPI data on Wednesday, PPI on Thursday, and retail sales on Friday, which could influence Treasury yields and growth stock valuations. Doximity's annual meeting is scheduled for August 27.
The company's valuation now hinges on expectations for AI Search monetization rather than current earnings. The key test will be converting user engagement into tangible revenue. Until then, the debate over Doximity's worth is likely to continue.
